ArticleThe British journal of radiology2019
Therapeutic efficacy, prognostic variables and clinical outcome of
Article in The British journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Comparative analysis of elastosonography and 18 F-FDG PET/CT in differentiating benign and malignant salivary gland tumors: a systematic review and meta-analysis.BMC oral health · 2025Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Evolving role ofProstate cancer and prostatic diseases · 2021Pooled it
- Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Article
- PSMA PET/CT improves precision diagnosis, treatment, and clinical decision-making in prostate cancer.American journal of translational research · 2026Review
- Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.The oncologist · 2025Article
- Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.Nuclear medicine and molecular imaging · 2025Review
- Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects.World journal of nuclear medicine · 2025Review
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Study of predictive factors for response toFrontiers in medicine · 2025Article
- Prognostic Role of PSMA-Targeted Imaging in Metastatic Castration-Resistant Prostate Cancer: An Overview.Biomedicines · 2024Review
- Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.Scientific reports · 2024Article
- Pre-treatmentMolecular imaging and biology · 2024Article
- Review
- 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.The oncologist · 2022Review
- Advances inPharmaceutics · 2022Review
- Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022Review
- Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.Therapeutic advances in medical oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic response, progression free survival (PFS), overall survival (OS) and clinical toxicity of
methodsWe examined the medical records of mCRPC patients who had undergone
resultsA total of 40 mCRPC patients (age range: 46-84 years; median 63 years), who had undergone
conclusionADVANCES IN KNOWLEDGE: The present work explored in a large teriary cancer care setting, the efficacy of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.